MedTrace Logo

The Effect of Prescription Medications in Marijuana Users

NCT00893074 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-08-03

Study results available
· View outcomes & findings →

Summary

A subset of heavy marijuana users have trouble quitting marijuana use and the number of those seeking treatment for problems related to marijuana is increasing. The purpose of this research study is to investigate whether dronabinol can reduce withdrawal effects associated with stopping marijuana use, if dronabinol can reduce the rewarding effects of smoked marijuana, and whether there are any cognitive performance deficits associated with dronabinol doses that produce such effects.

Conditions

  • Marijuana Abuse

Interventions

DRUG

Dronabinol 30mg/day

10mg dronabinol administered 3x/day for 5 days

DRUG

Dronabinol 60mg/day

20mg dronabinol administered 3x/day for 5 days

DRUG

Dronabinol 120mg/day

40mg dronabinol administered 3x/day for 5 days

DRUG

Placebo

placebo dronabinol administered 3x/day for 5 days

Sponsors & Collaborators

Principal Investigators

  • Ryan Vandrey, Ph.D. · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00893074 on ClinicalTrials.gov